HG SEMI(06908): The subscription rate for the rights issue is approximately 74.74%
Hongguang Semiconductor (06908) announces that as of the record date, the total number of issued shares is 751 million shares. According to the supply...
HG SEMI (06908) announces that as of the record date, the total number of issued shares is 751 million shares. According to the rights issue application, the total number of rights issue shares is 188 million shares. The Board of Directors declares that as of 15 January 2025 (Wednesday) at 4:00 pm (the deadline for acceptance), a total of three valid applications under provisional allotment letters have been received and accepted, involving a total of 140 million rights issue shares (equivalent to approximately 74.74% of the rights issue shares under provisional allotment). As of the record date, there are no ineligible shareholders, therefore there are no unsubscribed rights issue shares by ineligible shareholders. As a result, the subscription rate for the rights issue is approximately 74.74%. The remaining 47.4315 million unsubscribed rights issue shares (equivalent to approximately 25.26% of the rights issue shares) will be subject to compensation arrangements.
Related Articles

HK Stock Market Move | RemeGen (09995) rose nearly 8% again, and multiple original research results on vedolizumab were released at the 2026 EAU conference.

HK Stock Market Move | CF PHARMTECH (02652) rose more than 21% in midday trading, with the innovative research and development pipeline for high-end respiratory system formulations entering a period of accelerated harvest.

CICC: Maintains Outperform rating on GENSCRIPT BIO (01548), lowers target price to HK$17.90.
HK Stock Market Move | RemeGen (09995) rose nearly 8% again, and multiple original research results on vedolizumab were released at the 2026 EAU conference.

HK Stock Market Move | CF PHARMTECH (02652) rose more than 21% in midday trading, with the innovative research and development pipeline for high-end respiratory system formulations entering a period of accelerated harvest.

CICC: Maintains Outperform rating on GENSCRIPT BIO (01548), lowers target price to HK$17.90.

RECOMMEND

European Carmakers Embrace China: Under Technology And Cost Pressure, Stellantis And Mercedes Seek Partnerships With Chinese Automakers
17/03/2026

HKEX Listing Mechanism Reform Revisited: How To Balance New Favorites And Established Names
17/03/2026

International Oil Prices Plunge Boosts U.S. Stocks; Morgan Stanley Chief Says Market Correction Nearing End
17/03/2026


